Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*

Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

(2011) Annita Kolnagou et al.   HEMOGLOBIN

Better survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature

(2010) Maria Marsella et al.   Annals of the New York Academy of Sciences

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

(2010) Annita Kolnagou et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

(2010) A. Pepe et al.   HAEMATOLOGICA

Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study

(2009) Alberto Roghi et al.   ANNALS OF HEMATOLOGY

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease

(2009) Adlette Inati et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients

(2009) George J. Kontoghiorghes   HEMOGLOBIN

Uses and Limitations of Serum Ferritin, Magnetic Resonance Imaging T2 and T2* in the Diagnosis of Iron Overload and in the Ferrikinetics of Normalization of the Iron Stores in Thalassemia Using the International Committee on Chelation Deferiprone/Deferoxamine Combination Protocol

(2009) Anita Kolnagou et al.   HEMOGLOBIN

Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major

(2009) Casey J. Brewer et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β-thalassemia major

(2009) Olympia Papakonstantinou et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major

(2008) W.-Y. Au et al.   HAEMATOLOGICA

Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Magnetic Resonance Imaging Assessment of Excess Iron in Thalassemia, Sickle Cell Disease and Other Iron Overload Diseases

(2008) John C. Wood et al.   HEMOGLOBIN

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation

(2008) Gian Luca Forni et al.   MOVEMENT DISORDERS